Phase I study of HFB200301, a first-in-class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS). This is an ASCO Meeting Abstract from the 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results